Bullich S - Search Results

1

Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers.

Farré M, Pérez-Mañá C, Papaseit E, Menoyo E, Pérez M, Martin S, Bullich S, Rojas S, Herance JR, Trampal C, Labeaga L, Valiente R. Farré M, et al. Among authors: bullich s. Br J Clin Pharmacol. 2014 Nov;78(5):970-80. doi: 10.1111/bcp.12421. Br J Clin Pharmacol. 2014. PMID: 24833043 Free PMC article. Clinical Trial.

2

Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: part 2--ketanserin displacement.

Catafau AM, Danus M, Bullich S, Nucci G, Llop J, Abanades S, Cunningham VJ, Eersels JL, Pavia J, Farre M. Catafau AM, et al. Among authors: bullich s. J Nucl Med. 2006 Jun;47(6):929-37. J Nucl Med. 2006. PMID: 16741301 Free article. Clinical Trial.

3

Test-retest variability and reliability of 123I-IBZM SPECT measurement of striatal dopamine D2 receptor availability in healthy volunteers and influence of iterative reconstruction algorithms.

Catafau AM, Bullich S, Danús M, Penengo MM, Cot A, Abanades S, Farré M, Pavía J, Ros D. Catafau AM, et al. Among authors: bullich s. Synapse. 2008 Jan;62(1):62-9. doi: 10.1002/syn.20465. Synapse. 2008. PMID: 17960766

4

Imaging cortical dopamine D1 receptors using [11C]NNC112 and ketanserin blockade of the 5-HT 2A receptors.

Catafau AM, Searle GE, Bullich S, Gunn RN, Rabiner EA, Herance R, Radua J, Farre M, Laruelle M. Catafau AM, et al. Among authors: bullich s. J Cereb Blood Flow Metab. 2010 May;30(5):985-93. doi: 10.1038/jcbfm.2009.269. Epub 2009 Dec 23. J Cereb Blood Flow Metab. 2010. PMID: 20029452 Free PMC article.

5

Biodistribution and radiation dosimetry of the glycine transporter-1 ligand 11C-GSK931145 determined from primate and human whole-body PET.

Bullich S, Slifstein M, Passchier J, Murthy NV, Kegeles LS, Kim JH, Xu X, Gunn RN, Herance R, Gispert JD, Gutiérrez A, Farré M, Laruelle M, Catafau AM. Bullich S, et al. Mol Imaging Biol. 2011 Aug;13(4):776-84. doi: 10.1007/s11307-010-0398-6. Mol Imaging Biol. 2011. PMID: 20730499 Clinical Trial.

6

Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1.

Gunn RN, Murthy V, Catafau AM, Searle G, Bullich S, Slifstein M, Ouellet D, Zamuner S, Herance R, Salinas C, Pardo-Lozano R, Rabiner EA, Farre M, Laruelle M. Gunn RN, et al. Among authors: bullich s. Synapse. 2011 Dec;65(12):1319-32. doi: 10.1002/syn.20966. Epub 2011 Aug 12. Synapse. 2011. PMID: 21688322

7

Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative.

Marquié M, Valero S, Castilla-Marti M, Martínez J, Rodríguez-Gómez O, Sanabria Á, Tartari JP, Monté-Rubio GC, Sotolongo-Grau O, Alegret M, Pérez-Cordón A, Roberto N, de Rojas I, Moreno-Grau S, Montrreal L, Hernández I, Rosende-Roca M, Mauleón A, Vargas L, Abdelnour C, Gil S, Esteban-De Antonio E, Espinosa A, Ortega G, Lomeña F, Pavia J, Vivas A, Tejero MÁ, Gómez-Chiari M, Simó R, Ciudin A, Hernández C, Orellana A, Benaque A, Ruiz A, Tárraga L, Boada M; FACEHBI study group. Marquié M, et al. Alzheimers Res Ther. 2020 Mar 31;12(1):37. doi: 10.1186/s13195-020-00602-9. Alzheimers Res Ther. 2020. PMID: 32234080 Free PMC article.

8

Multitracer model for staging cortical amyloid deposition using PET imaging.

Collij LE, Heeman F, Salvadó G, Ingala S, Altomare D, de Wilde A, Konijnenberg E, van Buchem M, Yaqub M, Markiewicz P, Golla SSV, Wottschel V, Wink AM, Visser PJ, Teunissen CE, Lammertsma AA, Scheltens P, van der Flier WM, Boellaard R, van Berckel BNM, Molinuevo JL, Gispert JD, Schmidt ME, Barkhof F, Lopes Alves I; ALFA Study, for the Alzheimer's Disease Neuroimaging Initiative; AMYPAD Consortium. Collij LE, et al. Neurology. 2020 Sep 15;95(11):e1538-e1553. doi: 10.1212/WNL.0000000000010256. Epub 2020 Jul 16. Neurology. 2020. PMID: 32675080 Free PMC article.

9

SPECT of serotonin transporters using 123I-ADAM: optimal imaging time after bolus injection and long-term test-retest in healthy volunteers.

Catafau AM, Pérez V, Penengo MM, Bullich S, Danús M, Puigdemont D, Pascual JC, Corripio I, Llop J, Perich J, Alvarez E. Catafau AM, et al. Among authors: bullich s. J Nucl Med. 2005 Aug;46(8):1301-9. J Nucl Med. 2005. PMID: 16085586 Free article.

10

Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: Part 1--pseudoequilibrium interval and quantification methods.

Catafau AM, Danus M, Bullich S, Llop J, Perich J, Cunningham VJ, Plaza P, Penengo MM, Eersels JL, Squassante L, Ros D, Barbanoj M. Catafau AM, et al. Among authors: bullich s. J Nucl Med. 2006 Jun;47(6):919-28. J Nucl Med. 2006. PMID: 16741300 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

83 results

Search Page